AtriCure (ATRC) Projected to Post Earnings on Thursday

AtriCure (NASDAQ:ATRC) is expected to announce its Q2 2026 results after the market closes on Thursday, July 23rd. Analysts expect the company to post earnings of $0.03 per share and revenue of $151.8370 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, July 23, 2026 at 4:30 PM ET.

AtriCure Stock Up 0.6%

Shares of NASDAQ ATRC opened at $34.54 on Thursday. AtriCure has a 1 year low of $25.36 and a 1 year high of $43.18. The firm’s 50 day moving average price is $29.02 and its 200 day moving average price is $31.63. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.18 and a current ratio of 4.29. The firm has a market cap of $1.75 billion, a P/E ratio of -345.40 and a beta of 1.24.

Wall Street Analyst Weigh In

ATRC has been the subject of several recent research reports. Wall Street Zen downgraded shares of AtriCure from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 2nd. Weiss Ratings lowered AtriCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, May 4th. Zacks Research cut shares of AtriCure from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 4th. Canaccord Genuity Group lifted their price objective on shares of AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Finally, Freedom Capital raised shares of AtriCure to a “strong-buy” rating in a research note on Wednesday, April 1st. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $48.71.

Insider Buying and Selling at AtriCure

In other news, Director Karen Prange sold 3,000 shares of the stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $28.65, for a total value of $85,950.00. Following the completion of the transaction, the director directly owned 26,373 shares in the company, valued at $755,586.45. This trade represents a 10.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 4.00% of the company’s stock.

Institutional Trading of AtriCure

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geneos Wealth Management Inc. bought a new stake in AtriCure during the second quarter worth approximately $37,000. Smartleaf Asset Management LLC raised its position in shares of AtriCure by 59.8% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock worth $46,000 after purchasing an additional 429 shares during the period. State of Wyoming purchased a new stake in shares of AtriCure during the fourth quarter valued at $75,000. Kemnay Advisory Services Inc. purchased a new stake in shares of AtriCure during the fourth quarter valued at $114,000. Finally, Strs Ohio acquired a new position in shares of AtriCure in the 1st quarter valued at $158,000. 99.11% of the stock is owned by institutional investors and hedge funds.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.